Scheme Withdrawn Sponsor buyer
Avista Healthcare Partners acquisition of Mayne Pharma Group
A$672m equity value
Announced 21 Feb 2025 · ASX: MYX · A$7.40 cash per share · 37% premium
Advisers
Mayne Pharma Group
Target
- Financial adviser
- Legal adviser
- Independent expert
- Tax adviser
- EY
(as Ernst & Young)
Cosette Pharmaceuticals
Acquirer
- Legal adviser
- Target
- Mayne Pharma Group
- Acquirer
- Cosette Pharmaceuticals (Cosette Pharmaceuticals Holdings)
- Sponsor
- Avista Healthcare Partners, Hamilton Lane
- Structure
- Scheme of arrangement
- Withdrawn
- 11 Dec 2025
- Sector
- Biotech and pharmaceuticals
Similar deals
- BDT & MSD Partners stake in DBG Health Aug 2025 · A$1.6bn · Biotech and pharmaceuticals
- BGH Capital acquisition of Aspen Pharmacare Asia Pacific business Jun 2026 · A$2.4bn · Biotech and pharmaceuticals
- TPG acquisition of Agilex Biolabs Sep 2026 · A$160m · Biotech and pharmaceuticals
- Telix Pharmaceuticals and ITM Isotope Technologies Munich SE merger Sep 2026 · A$3.3bn · Biotech and pharmaceuticals
- Animalcare Group acquisition of Randlab Group Dec 2024 · A$120m · Biotech and pharmaceuticals
Sources
- 21 Feb 2025 Mayne Pharma enters Scheme Implementation Deed with Cosette ASX
- 24 Feb 2025 Cosette Pharmaceuticals' $430 Million Acquisition of Mayne Pharma Group globallegalchronicle.com
- 25 Feb 2025 Corrs advises Cosette on A$672 million acquisition of Mayne corrs.com.au
- 15 May 2025 ASIC registration of Mayne Pharma scheme booklet ASX
- 4 Jun 2025 Mayne Pharma receives purported notice to terminate SID ASX
- 13 Jun 2025 MYX receives further purported notice to terminate SID ASX
- 11 Dec 2025 Mayne Pharma terminates Scheme Implementation Deed ASX